Eli Lilly and Company $LLY Shares Purchased by Principle Wealth Partners LLC

Principle Wealth Partners LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 6,755 shares of the company’s stock after buying an additional 139 shares during the period. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $5,266,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $27,000. Blume Capital Management Inc. increased its stake in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the period. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the period. Finally, IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter valued at about $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $812.33 on Thursday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a 50-day moving average of $762.81 and a two-hundred day moving average of $766.75. The stock has a market cap of $768.84 billion, a price-to-earnings ratio of 53.09, a PEG ratio of 1.14 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the company posted $3.92 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LLY shares. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the company an “overweight” rating in a research report on Thursday, October 9th. Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. HSBC raised their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.